Vancouver, British Columbia--(Newsfile Corp. - January 17, 2019) - Alliance Growers Corp. (CSE: ACG) (FWB: 1LA)
(WKN: A2DFYX) (OTCQB: ALGWF) ("Alliance Growers" or "the Company") is pleased to report the Company is extremely well positioned to
capitalize on the growing CBD market in Canada's hemp industry by having access to and sharing in the profits of the proprietary
CBD Dana strain. The production of hemp, a form of cannabis with THC levels below 0.3%, conjunctively increased the U.S. and the
Canadian market size for "CBD Dana" hemp tissue culture plantlets.
"Canadians will benefit by virtue of there being a bigger pie and we will continue to compete. I'm sure we can with our 20 years
of experience," said Russ Crawford, president of the Canadian Hemp Trade Alliance, adding the U.S. farm bill has legitimized hemp
around the world. Crawford said Hempco Canada is about to commission its large hemp facility near Leduc, Alta. There have been
other companies looking to build food processing and cannabinoid extraction facilities in Canada, he added.
Commenting on Alliance Growers position to capitalize on the growing CBD market in Canada, Dennis Petke, Alliance Growers
President and CEO stated, "Alliance is very fortunate to have developed a close strategic relationship with Pharmagreen such that
the Company will be able to enjoy significant profits from selling the much sought after superior CBD Dana plantlets worldwide as
well as high profit margins from joint venture commercial hemp operations with Canadian hemp farmers."
Alliance Growers has secured access to the proprietary CBD strain named CBD Dana, a product used in the treatment of multiple
sclerosis, epilepsy, potent inhibitor of cancer cell proliferation, metastasis, and tumor growth as well as other symptoms.
The unique strain has been tested for a content of at least 10 percent CBD (and as high as 14% CBD) and less than 0.3 percent
THC. This CBD yield is substantially greater than traditional hemp strains which typically have at most a 1 percent content. The
lower THC content allows the strain to be classified as "industrial hemp" which makes it ideal for cultivation with less
restrictive regulation.
The female plantlets produced in the tissue culture lab at the Cannabis Biotech Complex will be available for hemp farmers on a
global scale. Providing hemp farmers with all female, fully rooted plantlets of the strain will provide a significant yield in CBD
production for hemp farmers.
About Pharmagreen Biotech, Inc. and WFS Pharmagreen Inc.
WFS Pharmagreen Inc. is a wholly owned Canadian based subsidiary of Pharmagreen Biotech, Inc., a publicly traded (OTC Venture:
PHBI) company. WFS Pharmagreen Inc. is a cannabis company that is becoming the largest producer of cannabis plantlets through a
proprietary tissue culture process with opportunity to become one of the largest players globally. Pharmagreen's mission is to
advance the technology of tissue culture science and to provide the highest quality 100% germ free, disease free and all
genetically the same plantlets of cannabis and other flora while offering full spectrum DNA testing for plant identification, live
genetics preservation using low temperature storage for various cannabis and horticulture plants; extraction of botanical oils
mainly CBD oil, and to deliver laboratory based services to the North American Cannabis and agriculture sectors. For further
information on the company progress on the construction of a 62,000 square foot "Cannabis Biotech Complex" please visit www.pharmagreen.ca
About Alliance Growers Corp.
Alliance Growers is a Diversified Global Medical Cannabis Company driven by the Company's 'Four Pillars' Organization Plan -
Cannabis Biotech Complex, Strategic ACMPR Investments, CBD Oil Supply and Distribution, and Research and Technology.
Alliance Growers is working with Pharmagreen Biotech Inc. advancing a new business partnership, to jointly develop and operate a
62,000-square foot facility, to be the first of its kind in Western Canada to house a DNA Botany lab, extraction facility and
Tissue Culture Plantlet Production facility to service the Cannabis market and agriculture market in general. The proposed Cannabis
Biotech Complex's main facility is the Cannabis Biotech Centre which will grow Cannabis plantlets using proprietary tissue culture
propagation, specifically utilizing the "Chibafreen Invitro Plant Production System", which allows for more tissue cultured
plantlets to be produced in less space and less time.
For further information, please visit the Company's website at www.alliancegrowers.com or the Company's profile at www.sedar.com.
If you would like to be added to Alliance Growers' news distribution list, please send your email address to newsletter@alliancegrowers.com.
For more information contact:
Dennis Petke
CEO, President and Director
Tel: 778-331-4266
DennisPetke@alliancegrowers.com
Rob Grace
Communications Consultant
Tel: 778-998-5431
RobDGrace@gmail.com
FOLLOW US:
Facebook
Twitter
LinkedIn
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE
FORWARD LOOKING INFORMATION
This news release contains forward-looking statements and forward-looking information within the meaning of applicable
securities laws. These statements relate to future events or future performance. All statements other than statements of historical
fact may be forward-looking statements or information. More particularly and without limitation, the news release contains
forward-looking statements and information relating to Company's corporate strategy. The forward-looking statements and information
are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the
Company's ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions
on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the
forward-looking statements and information since no assurance can be given that they will prove to be correct.
Forward-looking statements and information are provided for the purpose of providing information about the current expectations
and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and
information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and
information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could
differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the
Company's ability to identify and complete additional suitable acquisitions to further the Company's growth as well as risks
associated with the medical marijuana industry in general, such as operational risks in development and production delays or
changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the
uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing
and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market;
ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals
and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place
undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned
that the foregoing list of factors is not exhaustive.
The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking
is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future
events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking
statements or information contained in this news release are expressly qualified by this cautionary statement.